Last week, Alejandro Picardi M.D. (Business Development), and Cintia Notcovich, Ph.D. (Biomanufacturing Manager), participated in the Integrated Continuous Biomanufacturing VI in Virgina, US.

The event brought together leading scientists from academia and the pharmaceutical industry to share their experiences in developing, integrating, and implementing innovative processes in continuous biomanufacturing.

This post highlights our three biggest takeaways. These are particularly significant for Stämm, as we focus on improving today’s biomanufacturing methods, overcoming the current bottlenecks, and building the facilities of the future. If that’s your goal as well, you should continue reading.

 

Future facilities have to deal with uncertain portfolio compositions and volume predictions.
 The industry must enhance continuous biomanufacturing processes to meet the rising demand for biological products. Future facilities should be multi-product and adaptable to uncertainties in drug demand and market dynamics while demonstrating robustness and cost-efficiency compared to fed-batch methods.

The market demands innovative facility design and automation:
 There’s a strong emphasis on developing convertible facilities with closed systems to operate in non-classified spaces. This adaptability, combined with single-use technologies, promises to improve sustainability and workflow efficiency.

Achieving a balance of flexibility, modularity, and simplicity together with automation and process control is vital for managing the uncertain compositions and volumes of future product portfolios.
 

FDA speakers highlight the importance of collaboration across different sectors.

A high point of the event was the participation of FDA speakers, who offered valuable insights into the regulatory landscape surrounding emerging technologies.

Their interaction with the audience sparked engaging discussions, emphasizing the need for early engagement and ongoing dialogue between regulatory bodies and the industry, as we navigate the future of biomanufacturing.

As we move forward, we must embrace the transformative potential continuous technologies bring to the scene. The biomanufacturing sector has a golden opportunity to redefine itself, improve productivity, and become more competitive in the life science landscape. The time for action is now, and the perfect mix is flexibility, automation, and continuous production.
 
 Is your company ready to take the first step toward redefining the facilities of the future?
 
 At Stämm, we are making biomanufacturing easy, scalable, repeatable.

Feel free to reach out to learn more at info@stamm.bio